ORKAEarnings•globenewswire•
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Sentiment:Negative (30)
Summary
First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 11, 2025 by globenewswire